Back to Search Start Over

Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity

Authors :
Zachariah DeFilipp
Jonathan U. Peled
Shuli Li
Jasmin Mahabamunuge
Zeina Dagher
Ann E. Slingerland
Candice Del Rio
Betsy Valles
Maria E. Kempner
Melissa Smith
Jami Brown
Bimalangshu R. Dey
Areej El-Jawahri
Steven L. McAfee
Thomas R. Spitzer
Karen K. Ballen
Anthony D. Sung
Tara E. Dalton
Julia A. Messina
Katja Dettmer
Gerhard Liebisch
Peter Oefner
Ying Taur
Eric G. Pamer
Ernst Holler
Michael K. Mansour
Marcel R.M. van den Brink
Elizabeth Hohmann
Robert R. Jenq
Yi-Bin Chen
Source :
Blood Advances, Vol 2, Iss 7, Pp 745-753 (2018)
Publication Year :
2018
Publisher :
Elsevier, 2018.

Abstract

Abstract: We hypothesized that third-party fecal microbiota transplantation (FMT) may restore intestinal microbiome diversity after allogeneic hematopoietic cell transplantation (allo-HCT). In this open-label single-group pilot study, 18 subjects were enrolled before allo-HCT and planned to receive third-party FMT capsules. FMT capsules were administered no later than 4 weeks after neutrophil engraftment, and antibiotics were not allowed within 48 hours before FMT. Five patients did not receive FMT because of the development of early acute gastrointestinal (GI) graft-versus-host disease (GVHD) before FMT (n = 3), persistent HCT-associated GI toxicity (n = 1), or patient decision (n = 1). Thirteen patients received FMT at a median of 27 days (range, 19-45 days) after HCT. Participants were able to swallow and tolerate all FMT capsules, meeting the primary study endpoint of feasibility. FMT was tolerated well, with 1 treatment-related significant adverse event (abdominal pain). Two patients subsequently developed acute GI GVHD, with 1 patient also having concurrent bacteremia. No additional cases of bacteremia occurred. Median follow-up for survivors is 15 months (range, 13-20 months). The Kaplan-Meier estimates for 12-month overall survival and progression-free survival after FMT were 85% (95% confidence interval, 51%-96%) and 85% (95% confidence interval, 51%-96%), respectively. There was 1 nonrelapse death resulting from acute GI GVHD (12-month nonrelapse mortality, 8%; 95% confidence interval, 0%-30%). Analysis of stool composition and urine 3-indoxyl sulfate concentration indicated improvement in intestinal microbiome diversity after FMT that was associated with expansion of stool-donor taxa. These results indicate that empiric third-party FMT after allo-HCT appears to be feasible, safe, and associated with expansion of recipient microbiome diversity. This trial was registered at www.clinicaltrials.gov as #NCT02733744.

Details

Language :
English
ISSN :
24739529
Volume :
2
Issue :
7
Database :
Directory of Open Access Journals
Journal :
Blood Advances
Publication Type :
Academic Journal
Accession number :
edsdoj.8d7fdaed624252a6555824c12cf057
Document Type :
article
Full Text :
https://doi.org/10.1182/bloodadvances.2018017731